, codenamed BBR2778
) is an immunosuppressant
drug, an analogue
with less toxic
effects on cardiac
tissue. It is being studied as an antineoplastic
for different kinds of cancer
, including solid tumors and hematological malignancies
such as non-Hodgkin lymphomas
It is also as potent as mitoxantrone in animal models of multiple sclerosis; however, results of human trials had not been published in 2007.
As of 2007, several phase III clinical trials of pixantrone are underway.